The studies of Oberli et al. (2017) developed an LNP vector to deliver an mRNA vaccine in melanoma models which induced a CD8+ response and tumour shrinkage with uptake into DCs, macrophages, and neutrophils [163]. This evidence concerns the gene CD8A and neoplasm.